Exploratory outcomes
MINIMAL RESIDUAL DISEASE (MRD)
Responses were durable, with a median duration of response (DOR) in all patients of 10.3 months. The median DORs were 1.9 (95% confidence interval (CI), not estimable (NE)–NE) months, 13.7 (95% CI = 2.9–NE) months, 10.0 (95% CI = 6.3–14.8) months and 12.9 (20.9–NE) months in patients treated with 50, 150, 450 and 800 × 10At the time of data cutoff (median follow-up, 18 months), median PFS across all dose groups was 8.8 (95% CI = 5.9–11.9) months and median OS was 34.2 (95% CI = 19.2–NE) months. Kaplan–Meier estimates of OS indicate that 79.2% and 57.7% of patients across all dose groups were alive at 1 year and 2 years, respectively. PFS and OS outcomes were dose-dependent (Fig. Fourteen of 15 patients (93.3%) who achieved ≥CR and underwent an assessment for bone marrow minimal residual disease (MRD) within 3 months before CR achieved MRD-negative status (10